Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 7/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 7/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452723 | 0.87 | MAPK14 (0.50) | MAPK14MAPK11CSNK1DCSNK1ECDC7 | |
| SCHEMBL5260762 | 0.82 | MAPK14 (0.46) | MAPK14MAPK11CSNK1DCSNK1ECDC7 | |
| SCHEMBL5464164 | 0.82 | MAPK14 (0.49) | MAPK14MAPK11CSNK1DCSNK1ECDC7 | |
| SCHEMBL5258781 | 0.82 | MAPK14 (0.46) | MAPK14MAPK11CSNK1DCSNK1ECDC7 | |
| SCHEMBL6220840 | 0.81 | MAPK14 (0.48) | MAPK14MAPK11CSNK1DCSNK1ELRRK2 | |
| SCHEMBL5261084 | 0.81 | MAPK14 (0.47) | MAPK14MAPK11CSNK1DCSNK1ECDC7 | |
| SCHEMBL14521815 | 0.81 | MAPK14 (0.57) | MAPK14MAPK11CSNK1DCSNK1ELRRK2 | |
| SCHEMBL5451984 | 0.80 | MAPK14 (0.47) | MAPK14MAPK11CSNK1DCSNK1ECDC7 | |
| SCHEMBL5261731 | 0.79 | MAPK14 (0.43) | MAPK14MAPK11CSNK1DCSNK1ECDC7 | |
| SCHEMBL5257663 | 0.79 | MAPK14 (0.43) | MAPK14MAPK11CSNK1DCSNK1ECDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | claimed |
| CN-1264377-A | Substituted pyrazoles as P38 kinase inhabitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | claimed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-7153959-B2 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-7071198-B1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-6979686-B1 | Substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1500657-A1 | Substituted pyrazoles as P38 kinase inhibitors | G.D. Searle LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1144403-B1 | SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS | SEARLE LLC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-6617324-B1 | Phenyl, cyclohexyl and pyridinyl or pyrimidinyl-substituted | G. D. SEARLE & COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6525059-B1 | Mitogen-activated protein kinases (MAP); | G. D. SEARLE & COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | disclosed |
| CN-1342157-A | Substituted pyrazoles ASP38 kinase inhibitors | SEARLE & CO (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1144403-A1 | SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-10-17 | — | — | EP | disclosed |
| CN-1273603-A | Attenuated respiratory syncytial virus | AMERICAN CYANAMID CO (US) | 2000-11-15 | — | — | CN | disclosed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | MAPK1, IL1R1, TNF | MAPK14 12/4885MAPK11 96/4885CSNK1D 254/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | MAPK14 7/4885MAPK11 42/4885CSNK1D 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.